Sophiris Bio Inc (NASDAQ:SPHS) shares traded up 3.2% during mid-day trading on Wednesday . The stock traded as high as $4.46 and last traded at $4.45, with a volume of 841,112 shares trading hands. The stock had previously closed at $4.31.

Several research analysts have recently issued reports on the stock. Maxim Group raised their target price on shares of Sophiris Bio from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. Echelon Wealth Partners reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The stock’s market cap is $92.63 million. The firm has a 50-day moving average of $4.03 and a 200-day moving average of $2.15.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. On average, equities research analysts forecast that Sophiris Bio Inc will post ($0.69) earnings per share for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.